German biotech Kupando raises 10M EUR to fund Phase 1b clinical trials of its innate immunity drug KUP101, a dual TLR agonist targeting solid tumours and drug-resistant infections.
https://thenextweb.com/news/kupando-series-a-kup101-phase-1b-innate-immunity #Tech #Startup #News #DeepTech #Kupando
German biotech Kupando raises €10M more to take its innate immunity drug into the clinic
An extension to the company’s Series A brings total funding to €23 million and clears the path for the first human trial of KUP101, a dual TLR agonist targeting solid tumours and ...
Pirates.BZ Tech Startup News